Atrium Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Atrium Therapeutics, Inc. carries a market capitalization of 208.18M, placing it among publicly traded companies globally. Its enterprise value stands at 715.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 208.18M |
| Enterprise Value | 715.71M |
Share Statistics
Atrium Therapeutics, Inc. currently has 17.11M shares outstanding.
| Shares Outstanding | 17.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 40.30, and the price-to-book ratio stands at 80.77.
| PE Ratio | N/A |
| PS Ratio | 40.30 |
| PB Ratio | 80.77 |
| P/TBV Ratio | 4.19 |
| P/FCF Ratio | -4.02 |
| P/OCF Ratio | -3.92 |
Enterprise Valuation
| EV / Sales | 29.40 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Atrium Therapeutics, Inc. maintains a current ratio of 13.04, meaning it holds 13.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.04 |
| Quick Ratio | 12.91 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -3,656.41 |
| Return on Assets (ROA) | -151.88 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 34,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Atrium Therapeutics, Inc.'s stock has declined approximately -17.49153% over the past 52 weeks. The 50-day moving average sits at 13.29, while the 200-day moving average is 13.56.
| Beta (5Y) | N/A |
| 52-Week Price Change | -17.49153% |
| 50-Day Moving Average | 13.29 |
| 200-Day Moving Average | 13.56 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Atrium Therapeutics, Inc. generated 24.34M in revenue and converted that into -222.02M in net income, yielding earnings per share of -3.03. EBITDA reached -235.37M, while operating income came in at -236.46M.
| Revenue | 24.34M |
| Gross Profit | N/A |
| Operating Income | -236.46M |
| Pretax Income | -221.98M |
| Net Income | -222.02M |
| EBITDA | -235.37M |
| EBIT | -236.46M |
| Earnings Per Share (EPS) | -3.03 |
Balance Sheet
Atrium Therapeutics, Inc. holds 267.85M in cash and equivalents against 2.68M in total debt, resulting in a net debt position of -267.85M. Total book value stands at 12.14M, with working capital of 263.66M providing operational flexibility.
| Cash & Cash Equivalents | 267.85M |
| Total Debt | 2.68M |
| Net Debt | -267.85M |
| Equity (Book Value) | 12.14M |
| Book Value Per Share | 0.17 |
| Working Capital | 263.66M |
Cash Flow
Atrium Therapeutics, Inc. produced -250.06M in operating cash flow over the past twelve months. After subtracting -6.32M in capital expenditures, free cash flow totaled -256.38M - equivalent to -3.49 per share.
| Operating Cash Flow | -250.06M |
| Capital Expenditures | -6.32M |
| Free Cash Flow | -256.38M |
| FCF Per Share | -3.49 |
Margins
Atrium Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -971.44 and net profit margin of -912.11 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -971.44 |
| Pretax Margin | -911.97 |
| Profit Margin | -912.11 |
| EBITDA Margin | -966.97 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -33.18 |
| FCF Yield | -24.85 |
Scores
Atrium Therapeutics, Inc. posts an Altman Z-Score of 8.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.66 |